Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 7/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.31 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211920 | 1.00 | MPO (0.37) | MPODRD2DRD3HTR1DCHRM1 | |
| SCHEMBL30940171 | 0.87 | MPO (0.51) | MPOELANECYP27A1CYP24A1 | |
| SCHEMBL19127634 | 0.87 | MPO (0.51) | MPOELANECYP27A1CYP24A1 | |
| SCHEMBL20165338 | 0.83 | ELANE (0.40) | MPOHSD11B1ELANECA2 | |
| SCHEMBL29756881 | 0.83 | ELANE (0.40) | MPOHSD11B1ELANECA2 | |
| SCHEMBL18845471 | 0.83 | METAP1 (0.37) | MPODRD2DRD3HTR1DCHRM1 | |
| SCHEMBL18850177 | 0.82 | MAOB (0.44) | MPODRD2DRD3HTR1DMAOB | |
| SCHEMBL5088660 | 0.82 | DRD2 (0.34) | MPODRD2DRD3HTR1DCHRM1 | |
| SCHEMBL18815835 | 0.81 | MPO (0.34) | MPODRD2DRD3HTR1DCHRM1 | |
| SCHEMBL30723775 | 0.80 | MPO (0.43) | MPOCYP27A1CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4699660-A2 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4021450-B1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025090847-A1 | ESTROGEN RECEPTOR DEGRADERS AND THEIR USE IN THE TREATMENT OF CANCER | BPGBIO, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-116253719-B | Estrogen and androgen receptor dual degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-118986983-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118834201-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-114667147-B | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-110612294-B | Human cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-4259137-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116744925-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116253719-A | Estrogen and androgen receptor dual degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115974840-A | Human cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-114656452-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-4021450-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114656452-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114667147-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022132652-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |